SCHEMBL5152669

SCHEMBL5152669

Cn1nc(-c2nc(OCc3ccccc3)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.51
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
PRKDC P78527 1/20 0.41
BRD4 O60885 1/20 0.41
ALDH1A1 P00352 3/20 0.40
CYP1A2 P05177 3/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
HSD17B10 Q99714 2/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
MGMT P16455 2/20 0.39
CDK1 P06493 1/20 0.39
CCNB1 P14635 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5152617 0.89 PKM (0.41) PKMBRD4ADORA2AADORA1ADORA2B
SCHEMBL5149124 0.89 PKM (0.41) PKMBRD4CDK1CCNB1CCNA2
SCHEMBL5149200 0.86 SRC (0.43) PKMPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL5148981 0.86 ADORA2A (0.40) PKMBRD4ALDH1A1CYP1A2CYP3A4
SCHEMBL5147960 0.86 HRH3 (0.40) PKMBRD4HSD17B10ADORA2AADORA1
SCHEMBL5150924 0.86 ADORA2A (0.41) PKMBRD4ALDH1A1CYP1A2CYP3A4
SCHEMBL5147984 0.81 BRD4 (0.43) PKMBRD4ALDH1A1CYP1A2CYP3A4
SCHEMBL5150911 0.80 MEN1 (0.49) ALDH1A1ADORA2AADORA1ADORA2BNPC1
SCHEMBL5149179 0.79 SMN1; SMN2 (0.42) BRD4SMN1; SMN2
SCHEMBL5152718 0.79 ADORA2A (0.43) ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
CN-1938296-A Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists ASTELLAS PHARMA INC (JP) 2007-03-28 CN disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 PKM 742/4885PIK3CD 2187/4885PIK3CA 1672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.